Eli Lilly and Company is a drug manufacturers-general business based in the US. Eli Lilly and Company shares (LLY.US) are listed on the NYSE and all prices are listed in US Dollars. Eli Lilly and Company employs 35,065 staff and has a trailing 12-month revenue of around $23.2 billion.
|Latest market close||$N/A|
|52-week range||$115.3609 - $206.54|
|50-day moving average||$171.7124|
|200-day moving average||$154.9002|
|Wall St. target price||$195.41|
|Dividend yield||$3.4 (1.65%)|
|Earnings per share (TTM)||$6.112|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Eli Lilly and Company shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3601. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $7.7 billion.
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$23.2 billion|
|Operating margin TTM||27.76%|
|Gross profit TTM||$17.6 billion|
|Return on assets TTM||9.84%|
|Return on equity TTM||131.77%|
|Market capitalisation||$197.2 billion|
TTM: trailing 12 months
There are currently 5.2 million Eli Lilly and Company shares held short by investors – that's known as Eli Lilly and Company's "short interest". This figure is 6.4% down from 5.6 million last month.
There are a few different ways that this level of interest in shorting Eli Lilly and Company shares can be evaluated.
Eli Lilly and Company's "short interest ratio" (SIR) is the quantity of Eli Lilly and Company shares currently shorted divided by the average quantity of Eli Lilly and Company shares traded daily (recently around 3.8 million). Eli Lilly and Company's SIR currently stands at 1.37. In other words for every 100,000 Eli Lilly and Company shares traded daily on the market, roughly 1370 shares are currently held short.
However Eli Lilly and Company's short interest can also be evaluated against the total number of Eli Lilly and Company shares, or, against the total number of tradable Eli Lilly and Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eli Lilly and Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Eli Lilly and Company shares in existence, roughly 10 shares are currently held short) or 0.0066% of the tradable shares (for every 100,000 tradable Eli Lilly and Company shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eli Lilly and Company.
Find out more about how you can short Eli Lilly and Company stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
|Total ESG score||32.36|
|Total ESG percentile||70.22|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||3|
Dividend payout ratio: 44.43% of net profits
Recently Eli Lilly and Company has paid out, on average, around 44.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.65% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 1.65% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $3.4 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 10 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 February 2021 (the "ex-dividend date").
Eli Lilly and Company's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $115.3609 up to $206.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.3734. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Find out more about the London Stock Exchange, what companies are listed on it and how to invest in the largest exchange in Europe.
Find out more about the Nikkei 225, some companies that make it up and how you can invest in the Nikkei 225.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.